Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Lymphoid 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Non-small Cell Lung Cancer Metastatic 1Neoplasm Metastasis 1Mesothelioma, Malignant 1Mesothelioma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Breast Neoplasms 1

Interventions

pembrolizumab 8Nivolumab 6Gemcitabine 5spartalizumab 3Magnetic Resonance Spectroscopy 3Cyclophosphamide 3Azacitidine 3toripalimab 2fludarabine 2epacadostat 2atezolizumab 2Therapeutics 2Sirolimus 2Paclitaxel 2Interleukin-2 2Epoetin Alfa 2Cisplatin 2Bevacizumab 2vocimagene amiretrorepvec 1vandetanib 1ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1tislelizumab 1temsirolimus 1sargramostim 1sapanisertib 1ruxolitinib 1rucaparib 1romidepsin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma × LY3023414 × Thoracic × Clear all
NCT01655225 2022-04-08

A Study of LY3023414 in Participants With Advanced Cancer

Eli Lilly and Company

Phase 1 Completed
156 enrolled
BreastLymphoidOther solid neoplasmThoracic

Mesothelioma, Malignant, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lymphoma, Lymphoma, Non-Hodgkin, Mesothelioma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡